Literature DB >> 15908032

Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes.

Tatsuhiro Ishida1, Masae Harada, Xin Yu Wang, Masako Ichihara, Kenji Irimura, Hiroshi Kiwada.   

Abstract

We recently reported that a second dose of polyethylene glycol (PEG) (M.W. 2000)-modified liposomes (mPEG2000-liposomes) is rapidly cleared from the blood and accumulates in the liver when injected twice in the same rat or mouse at several-day intervals (referred to as the "accelerated blood clearance (ABC) phenomenon"). In the present study we observed that a high dose (5 micromol/kg) of conventional liposomes (CL: without a PEG-coating) can induce the same phenomenon, while a low lipid dose (0.001 micromol/kg) did not. The induction of the phenomenon by mPEG2000-liposomes decreased with increasing first dose (0.001-5 micromol/kg). We observed a strong inverse relationship between the dose of initially injected PEG2000-liposomes and the extent to which the ABC phenomenon was induced: the higher the dose the smaller the phenomenon. Increasing the PEG density at the liposome surface beyond 5 mol% attenuated rather than induced the induction of the phenomenon, but elongation of the PEG chain length up to M.W. 5000, had no effect. In a series of hematological, serum-biochemical and histopathological safety evaluations we observed neither acute toxicity nor any signs of hepatic damage during the induction of the ABC phenomenon. Morphological examination of the liver by transmission electron microscopy (TEM) showed extensive accumulation of the second dose of mPEG2000-liposomes in the Kupffer cells, even already after 15 min, suggesting that the PEG liposomes had somehow lost the protective effect of the surface-grafted PEG against rapid clearance. The observations reported in this paper may have a considerable impact on the design and engineering of PEGylated liposomal formulations for use in multiple drug therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15908032     DOI: 10.1016/j.jconrel.2005.04.003

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  59 in total

Review 1.  Nanoparticulate systems for drug delivery and targeting to the central nervous system.

Authors:  Emanuela Fabiola Craparo; Maria Luisa Bondì; Giovanna Pitarresi; Gennara Cavallaro
Journal:  CNS Neurosci Ther       Date:  2010-10-15       Impact factor: 5.243

2.  Ultrasound radiation force enables targeted deposition of model drug carriers loaded on microbubbles.

Authors:  Aaron F H Lum; Mark A Borden; Paul A Dayton; Dustin E Kruse; Scott I Simon; Katherine W Ferrara
Journal:  J Control Release       Date:  2005-12-27       Impact factor: 9.776

3.  Acoustically-active microbubbles conjugated to liposomes: characterization of a proposed drug delivery vehicle.

Authors:  Azadeh Kheirolomoom; Paul A Dayton; Aaron F H Lum; Erika Little; Eric E Paoli; Hairong Zheng; Katherine W Ferrara
Journal:  J Control Release       Date:  2006-12-23       Impact factor: 9.776

Review 4.  Immunological risk of injectable drug delivery systems.

Authors:  Wim Jiskoot; Rianne M F van Schie; Myrra G Carstens; Huub Schellekens
Journal:  Pharm Res       Date:  2009-02-27       Impact factor: 4.200

Review 5.  Biomimetic nanoparticle technology for cardiovascular disease detection and treatment.

Authors:  Joon Ho Park; Diana Dehaini; Jiarong Zhou; Maya Holay; Ronnie H Fang; Liangfang Zhang
Journal:  Nanoscale Horiz       Date:  2019-06-28       Impact factor: 10.989

Review 6.  Liposomes in tissue engineering and regenerative medicine.

Authors:  Nelson Monteiro; Albino Martins; Rui L Reis; Nuno M Neves
Journal:  J R Soc Interface       Date:  2014-12-06       Impact factor: 4.118

Review 7.  Nanomedicines for renal disease: current status and future applications.

Authors:  Nazila Kamaly; John C He; Dennis A Ausiello; Omid C Farokhzad
Journal:  Nat Rev Nephrol       Date:  2016-10-31       Impact factor: 28.314

8.  Questioning the Use of PEGylation for Drug Delivery.

Authors:  Johan J F Verhoef; Thomas J Anchordoquy
Journal:  Drug Deliv Transl Res       Date:  2013-12       Impact factor: 4.617

Review 9.  Nanogels: An overview of properties, biomedical applications and obstacles to clinical translation.

Authors:  Kruti S Soni; Swapnil S Desale; Tatiana K Bronich
Journal:  J Control Release       Date:  2015-11-10       Impact factor: 9.776

10.  Accelerated Blood Clearance Phenomenon Reduces the Passive Targeting of PEGylated Nanoparticles in Peripheral Arterial Disease.

Authors:  Hyung-Jun Im; Christopher G England; Liangzhu Feng; Stephen A Graves; Reinier Hernandez; Robert J Nickles; Zhuang Liu; Dong Soo Lee; Steve Y Cho; Weibo Cai
Journal:  ACS Appl Mater Interfaces       Date:  2016-07-07       Impact factor: 9.229

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.